DaVita Stock - Analyst consensus and sector backdrop on a quiet news day
19.06.2026 - 17:54:15 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 17:53 CET. Details in the imprint.
DaVita (US23804L1035) enters the end of the week without a fresh market-moving company announcement. With no new filings or major headlines today from regulators or leading financial wires, the focus shifts to how the stock screens against analyst expectations and US healthcare peers.
Background and data on DaVita stock
Key figures, regulatory filings and previous news help put DaVita's valuation and risk profile into context for investors.
What recent numbers show
DaVita last reported quarterly results on 05/02/2024, posting net income from continuing operations of $1.84 per share, compared with $1.58 a year earlier, according to its first-quarter 2024 earnings release. Revenue for the period rose to roughly $3.07 billion, reflecting stable demand for dialysis services in the United States.
Management maintained its full-year 2024 operating income guidance range between $1.75 billion and $1.90 billion in that update, signaling confidence in cost control and payer mix. The company also highlighted continued investment in clinical initiatives and technology to support its network of dialysis centers.
Analyst consensus and valuation lens
Without fresh headlines today, investors often look at the analyst consensus as an anchor for expectations. Data from major financial portals show a mixed but generally constructive stance, with a majority of brokers rating DaVita at Hold or Buy and only a small minority on the Sell side.
Recent consensus compilations indicate that the average 12-month price target sits modestly above the current market price, implying limited but positive upside under base-case scenarios. Against this backdrop, DaVita trades on earnings multiples that are broadly in line with other mature US healthcare-services names.
How DaVita compares with peers
On Fridays, many portfolio managers review sector performance, and DaVita naturally gets compared with diversified hospital operators and managed-care groups in the United States. While DaVita focuses on dialysis, its earnings are still influenced by broader reimbursement trends that also affect other healthcare providers.
US healthcare-services stocks have shown relatively defensive characteristics in recent volatile markets, with stable cash flows and high barriers to entry cited as key features. DaVita's narrow specialization in kidney care means that its correlation with hospital and insurer earnings is imperfect but still meaningful for sector-level allocations.
How the company makes money
DaVita generates most of its revenue from operating outpatient dialysis centers and providing related laboratory services for patients with chronic kidney failure. The business model relies on long-term patient relationships, reimbursement from public and private payers, and disciplined cost management across its clinic network.
Where the stock trades today
DaVita shares (US23804L1035) trade on the New York Stock Exchange at approximately $141.00 as of 06/19/2026, 17:30 CET.
Key facts on DaVita stock
- Company: DaVita Inc.
- ISIN: US23804L1035
- Ticker: DVA
- Venue: NYSE
- Price (as of 06/19/2026, 17:30 CET): 141.00 USD
- Sector / Industry: Health Care - Health Care Providers & Services
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
